| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | GRS; BFL1; ACC-1; ACC-2; HBPA1; BCL2L5 |
| WB Predicted band size | 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human BCL2A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于BCL2A1抗体的参考文献示例(内容为虚构，仅用于格式参考)：
1. **文献名称**: *BCL2A1 as a resistance factor in cancer therapy*
**作者**: Smith A, et al.
**摘要**: 本研究利用BCL2A1特异性抗体(克隆号：XX-1B5)通过免疫印迹和免疫组化分析，发现BCL2A1在化疗耐药肿瘤中高表达，其过表达通过抑制线粒体凋亡途径降低癌细胞对顺铂的敏感性。
2. **文献名称**: *BCL2A1 regulates inflammatory response in myeloid cells*
**作者**: Lee JH, et al.
**摘要**: 通过抗BCL2A1抗体(货号：Ab-123)阻断蛋白功能，研究发现BCL2A1在巨噬细胞中调控NF-κB信号通路，促进促炎细胞因子(如IL-6和TNF-α)的分泌，提示其在自身免疫疾病中的潜在作用。
3. **文献名称**: *Targeting BCL2A1 in hematological malignancies*
**作者**: Rossi M, et al.
**摘要**: 使用BCL2A1单克隆抗体(商品名：Anti-BCL2A1-mAb)在急性髓系白血病(AML)模型中验证其治疗潜力。结果显示抗体通过抑制BCL2A1与促凋亡蛋白的相互作用，显著增强肿瘤细胞对BH3模拟剂的敏感性。
4. **文献名称**: *BCL2A1 expression correlates with poor prognosis in solid tumors*
**作者**: Zhang Y, et al.
**摘要**: 基于多组织微阵列的BCL2A1抗体(克隆号：BCL2A1/456)染色分析，发现BCL2A1在乳腺癌和肺癌中的高表达与患者总生存期缩短相关，提示其可作为预后标志物及治疗靶点。
(注：上述文献为示例，实际引用需根据真实发表研究调整。)
The BCL2A1 antibody targets the BCL-2-related protein A1 (BCL2A1), a member of the BCL-2 family of apoptosis-regulating proteins. BCL2A1. also known as Bfl-1. functions as an anti-apoptotic protein by inhibiting mitochondrial outer membrane permeabilization, thereby blocking caspase activation and cell death. It is primarily expressed in hematopoietic cells and certain cancers, where its overexpression contributes to tumor survival, chemoresistance, and immune evasion.
BCL2A1 antibodies are critical tools for studying its expression, localization, and interaction with pro-apoptotic proteins like BIM or BAX. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to investigate BCL2A1's role in cancers (e.g., lymphoma, leukemia) and inflammatory diseases. Commercially available clones (e.g., CL4883. D5Z4Z) are often validated for specificity across human, mouse, or rat samples.
Research highlights BCL2A1's clinical relevance in therapy resistance, making it a potential biomarker or therapeutic target. However, challenges remain in distinguishing BCL2A1 from other BCL-2 homologs due to structural similarities, necessitating rigorous antibody validation. Ongoing studies explore BCL2A1's regulation by NF-κB signaling and its impact on tumor microenvironments, underscoring its dual role in apoptosis and immune modulation.
×
